{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:50:32Z","timestamp":1791600632438,"version":"4.3.4"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jfma.2020.05.018","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:39:50Z","timestamp":1591231190000},"page":"S51-S57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"S1","title":["Treatment of pulmonary disease caused by Mycobacterium kansasii"],"prefix":"10.1016","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8809-0546","authenticated-orcid":false,"given":"Hung-Ling","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Liang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Hsiang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8328-8684","authenticated-orcid":false,"given":"Inn-Wen","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2020.05.018_bib1","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1183\/09031936.00149212","article-title":"The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study","volume":"42","author":"Hoefsloot","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jfma.2020.05.018_bib2","doi-asserted-by":"crossref","first-page":"36299","DOI":"10.1038\/srep36299","article-title":"Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in a Chinese tuberculosis tertiary Care center","volume":"6","author":"Duan","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2020.05.018_bib3","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01788-17","article-title":"Drug susceptibility profiling and genetic determinants of drug resistance in Mycobacterium kansasii","volume":"62","author":"Bakula","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jfma.2020.05.018_bib4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40506-016-0086-4","article-title":"Treatment of non-tuberculous mycobacterial lung disease","volume":"8","author":"Philley","year":"2016","journal-title":"Curr Treat Options Infect Dis"},{"key":"10.1016\/j.jfma.2020.05.018_bib5","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0272-5231(02)00016-3","article-title":"Management of disease due to Mycobacterium kansasii","volume":"23","author":"Griffith","year":"2002","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.jfma.2020.05.018_bib6","first-page":"501","article-title":"Mycobacterium kansasii and M. scrofulaceum isolates from HIV-negative South African gold miners: incidence, clinical significance and radiology","volume":"3","author":"Corbett","year":"1999","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.jfma.2020.05.018_bib7","volume":"5","author":"Johnston","year":"2017","journal-title":"Mycobac kansasii Microbiol Spectr"},{"key":"10.1016\/j.jfma.2020.05.018_bib8","doi-asserted-by":"crossref","first-page":"16300","DOI":"10.1038\/s41598-017-16559-z","article-title":"Epidemiology and predictors of NTM pulmonary infection in Taiwan - a retrospective, five-year multicenter study","volume":"7","author":"Huang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2020.05.018_bib9","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/thoraxjnl-2017-210929","article-title":"Introducing the new BTS Guideline: management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"72","author":"Haworth","year":"2017","journal-title":"Thorax"},{"key":"10.1016\/j.jfma.2020.05.018_bib10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jfma.2020.05.018_bib11","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/thx.49.5.442","article-title":"Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol","volume":"49","year":"1994","journal-title":"Thorax"},{"key":"10.1016\/j.jfma.2020.05.018_bib12","first-page":"1048","article-title":"Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii","volume":"128","author":"Ahn","year":"1983","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jfma.2020.05.018_bib13","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0962-8479(95)90541-3","article-title":"Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy","volume":"76","author":"Campbell","year":"1995","journal-title":"Tuber Lung Dis"},{"key":"10.1016\/j.jfma.2020.05.018_bib14","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1183\/09031936.00024008","article-title":"Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease","volume":"33","author":"Santin","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jfma.2020.05.018_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139621","article-title":"Clinical significance of Mycobacterium kansasii isolates from respiratory specimens","volume":"10","author":"Moon","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.jfma.2020.05.018_bib16","first-page":"R147","article-title":"Opportunist mycobacteria in England and Wales: 1982 to 1994","volume":"6","author":"Lamden","year":"1996","journal-title":"Commun Dis Rep - CDR Rev"},{"key":"10.1016\/j.jfma.2020.05.018_bib17","first-page":"1007","article-title":"The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey","volume":"135","author":"O'Brien","year":"1987","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jfma.2020.05.018_bib18","doi-asserted-by":"crossref","first-page":"698","DOI":"10.7326\/0003-4819-129-9-199811010-00004","article-title":"Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study","volume":"129","author":"Bloch","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2020.05.018_bib19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3201\/eid170310060","article-title":"Nontuberculous mycobacteria in respiratory tract infections, eastern Asia","volume":"17","author":"Simons","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jfma.2020.05.018_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.rmed.2019.03.015","article-title":"Outcome of patients with and poor prognostic factors for Mycobacterium kansasii-pulmonary disease","volume":"151","author":"Liu","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.jfma.2020.05.018_bib21","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1378\/chest.14-1297","article-title":"The significance of Mycobacterium abscessus subspecies abscessus isolation during Mycobacterium avium complex lung disease therapy","volume":"147","author":"Griffith","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.jfma.2020.05.018_bib22","doi-asserted-by":"crossref","first-page":"17826","DOI":"10.1038\/s41598-018-36255-w","article-title":"Predictors of developing Mycobacterium kansasii pulmonary disease within 1 year among patients with single isolation in multiple sputum samples: a retrospective, longitudinal, multicentre study","volume":"8","author":"Huang","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2020.05.018_bib23","first-page":"625","article-title":"Obstructive airway disease in patients with treated pulmonary tuberculosis","volume":"103","author":"Snider","year":"1971","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jfma.2020.05.018_bib24","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1086\/513666","article-title":"Mycobacterium kansasii disease in patients infected with human immunodeficiency virus","volume":"24","author":"Campo","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2020.05.018_bib25","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1164\/rccm.200402-162OC","article-title":"Mortality prediction in pulmonary Mycobacterium kansasii infection and human immunodeficiency virus","volume":"170","author":"Marras","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jfma.2020.05.018_bib26","series-title":"Performance standards for susceptibility testing of mycobacteria, nocardia spp. and other aerobic actinomycetes. CLSI doument M62Ed1","author":"Woods","year":"2018"},{"key":"10.1016\/j.jfma.2020.05.018_bib27","series-title":"Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes","author":"Woods","year":"2011"},{"key":"10.1016\/j.jfma.2020.05.018_bib28","first-page":"10","article-title":"Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii","volume":"135","author":"Ahn","year":"1987","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jfma.2020.05.018_bib29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1128\/CMR.05030-11","article-title":"Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria","volume":"25","author":"Brown-Elliott","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jfma.2020.05.018_bib30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0041-3879(76)80005-0","article-title":"Acquired resistance to rifampicin by Mycobacterium kansasii","volume":"57","author":"Davidson","year":"1976","journal-title":"Tubercle"},{"key":"10.1016\/j.jfma.2020.05.018_bib31","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/clinids\/18.5.736","article-title":"Rifampin-resistant Mycobacterium kansasii","volume":"18","author":"Wallace","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2020.05.018_bib32","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1128\/AAC.45.11.3056-3058.2001","article-title":"Rifampin resistance in Mycobacterium kansasii is associated with rpoB mutations","volume":"45","author":"Klein","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jfma.2020.05.018_bib33","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jinf.2015.12.007","article-title":"The antimicrobial susceptibility of non-tuberculous mycobacteria","volume":"72","author":"Cowman","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.jfma.2020.05.018_bib34","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3389\/fmicb.2016.02097","article-title":"Mycobacterium kansasii subtype I is associated with clarithromycin resistance in China","volume":"7","author":"Li","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jfma.2020.05.018_bib35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijantimicag.2009.09.023","article-title":"In\u00a0vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands","volume":"35","author":"van Ingen","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jfma.2020.05.018_bib36","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/jac\/dki111","article-title":"In\u00a0vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii","volume":"55","author":"Guna","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jfma.2020.05.018_bib37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF01971272","article-title":"Susceptibility of Mycobacterium kansasii to ethambutol and its combination with rifamycins, ciprofloxacin and isoniazid","volume":"11","author":"Hjelm","year":"1992","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jfma.2020.05.018_bib38","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/jac\/dkp238","article-title":"Clinical manifestations, antibiotic susceptibility and molecular analysis of Mycobacterium kansasii isolates from a university hospital in Taiwan","volume":"64","author":"Wu","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jfma.2020.05.018_bib39","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1099\/jmm.0.45965-0","article-title":"Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates","volume":"54","author":"da Silva Telles","year":"2005","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jfma.2020.05.018_bib40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0196-4399(85)80012-X","article-title":"Identification and drug susceptibility test results for Mycobacterium spp","volume":"7","author":"Good","year":"1985","journal-title":"Clin Microbiol Newsl"},{"key":"10.1016\/j.jfma.2020.05.018_bib41","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1086\/378742","article-title":"Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study","volume":"37","author":"Griffith","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2020.05.018_bib42","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1378\/chest.129.3.771","article-title":"Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome","volume":"129","author":"Shitrit","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.jfma.2020.05.018_bib43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.rmed.2019.01.012","article-title":"Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease","volume":"148","author":"Moon","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.jfma.2020.05.018_bib44","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1128\/AAC.48.12.4562-4565.2004","article-title":"Comparative in\u00a0vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii","volume":"48","author":"Alcaide","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jfma.2020.05.018_bib45","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3349\/ymj.2010.51.4.552","article-title":"Clinical characteristics and treatment outcomes of Mycobacterium kansasii lung disease in Korea","volume":"51","author":"Park","year":"2010","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.jfma.2020.05.018_bib46","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0962-8479(95)90550-2","article-title":"Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy","volume":"76","author":"Sauret","year":"1995","journal-title":"Tuber Lung Dis"},{"key":"10.1016\/j.jfma.2020.05.018_bib47","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.3389\/fmicb.2018.02271","article-title":"Therapy for Mycobacterium kansasii infection: beyond 2018","volume":"9","author":"DeStefano","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jfma.2020.05.018_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/jmm.0.000198","article-title":"Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria","volume":"65","author":"Soni","year":"2016","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jfma.2020.05.018_bib49","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ijid.2018.04.4200","article-title":"Comparative in\u00a0vitro activities of several oxazolidinones against Mycobacterium kansasii","volume":"73","author":"Shoen","year":"2018","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jfma.2020.05.018_bib50","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/14787210.2016.1225498","article-title":"Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index","volume":"14","author":"Wasserman","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jfma.2020.05.018_bib51","series-title":"Safety and tolerability of long term use of tedizolid for treatment of nontuberculous mycobacterial infections. Open Forum Infectious Diseases","author":"Kim","year":"2016"},{"key":"10.1016\/j.jfma.2020.05.018_bib52","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chest.2017.04.175","article-title":"Safety and effectiveness of clofazimine for primary and refractory nontuberculous mycobacterial infection","volume":"152","author":"Martiniano","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.jfma.2020.05.018_bib53","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1378\/chest.124.4.1482","article-title":"Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine","volume":"124","author":"Field","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.jfma.2020.05.018_bib54","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1378\/chest.15-0543","article-title":"Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and\/or rifampin","volume":"149","author":"Jarand","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jfma.2020.05.018_bib55","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1128\/jcm.24.6.976-981.1986","article-title":"Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth","volume":"24","author":"Wallace","year":"1986","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jfma.2020.05.018_bib56","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00665-19","article-title":"In\u00a0vitro activity of bedaquiline and delamanid against nontuberculous mycobacteria, including macrolide-resistant clinical isolates","volume":"63","author":"Kim","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jfma.2020.05.018_bib57","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.mayocp.2018.12.011","article-title":"Pharmacotherapy approaches in nontuberculous mycobacteria infections","volume":"94","author":"Shulha","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jfma.2020.05.018_bib58","doi-asserted-by":"crossref","first-page":"S440","DOI":"10.1093\/clinids\/5.Supplement_3.S440","article-title":"Adverse effects of rifampin","volume":"5","author":"Grosset","year":"1983","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.jfma.2020.05.018_bib59","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005889","article-title":"The rare ethambutol-induced optic neuropathy: a case-report and literature review","volume":"96","author":"Song","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jfma.2020.05.018_bib60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000013861","article-title":"Aminoglycoside antibiotics","volume":"5","author":"Forge","year":"2000","journal-title":"Audiol Neurotol"},{"key":"10.1016\/j.jfma.2020.05.018_bib61","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2165\/00002018-199309050-00004","article-title":"Adverse effects of macrolide antibacterials","volume":"9","author":"Periti","year":"1993","journal-title":"Drug Saf"},{"key":"10.1016\/j.jfma.2020.05.018_bib62","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1183\/09031936.00169114","article-title":"The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease","volume":"45","author":"Winthrop","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jfma.2020.05.018_bib63","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ejim.2005.12.003","article-title":"Torsades de pointes induced by antibiotics","volume":"17","author":"Justo","year":"2006","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jfma.2020.05.018_bib64","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1164\/rccm.201402-0385CI","article-title":"Macrolide antibiotics and the risk of cardiac arrhythmias","volume":"189","author":"Albert","year":"2014","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664620302084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664620302084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:42:36Z","timestamp":1760539356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664620302084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":64,"alternative-id":["S0929664620302084"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2020.05.018","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of pulmonary disease caused by Mycobacterium kansasii","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2020.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}